CO5090889A1 - Metodo para identificar sustancias para el tratamiento de transtornos asociados con apoptosis mediada por c-jun - Google Patents

Metodo para identificar sustancias para el tratamiento de transtornos asociados con apoptosis mediada por c-jun

Info

Publication number
CO5090889A1
CO5090889A1 CO99054518A CO99054518A CO5090889A1 CO 5090889 A1 CO5090889 A1 CO 5090889A1 CO 99054518 A CO99054518 A CO 99054518A CO 99054518 A CO99054518 A CO 99054518A CO 5090889 A1 CO5090889 A1 CO 5090889A1
Authority
CO
Colombia
Prior art keywords
jun
treatment
associated disorders
identifying substances
apoptosis mediated
Prior art date
Application number
CO99054518A
Other languages
English (en)
Inventor
Axel Behrens
Erwin F Wagner
Maria Sibilia
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5090889A1 publication Critical patent/CO5090889A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un método para identificar sustancias para el tratamiento de trastornos mediados por c-Jun, caracterizado porque se ensayan las sustancias en cuanto a su capacidad para inhibir la fosforilación N-terminal de c-Jun.
CO99054518A 1998-08-31 1999-08-27 Metodo para identificar sustancias para el tratamiento de transtornos asociados con apoptosis mediada por c-jun CO5090889A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98116415A EP0984070A1 (en) 1998-08-31 1998-08-31 Method for identifying substances for the treatment of disorders associated with c-Jun-mediated apoptosis

Publications (1)

Publication Number Publication Date
CO5090889A1 true CO5090889A1 (es) 2001-10-30

Family

ID=8232547

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99054518A CO5090889A1 (es) 1998-08-31 1999-08-27 Metodo para identificar sustancias para el tratamiento de transtornos asociados con apoptosis mediada por c-jun

Country Status (5)

Country Link
EP (1) EP0984070A1 (es)
AU (1) AU5855899A (es)
CO (1) CO5090889A1 (es)
UY (1) UY25687A1 (es)
WO (1) WO2000012754A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10036501B4 (de) * 2000-07-25 2004-08-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur Messung der JNK/SAPKs-Aktivität mittels der Bestimmung der Phosphorylierung von Transkriptionsfaktoren
US7247767B2 (en) 2004-01-21 2007-07-24 Boehringer Ingelheim International Gmbh Mouse model for psoriasis and psoriatic arthritis
US20060148996A1 (en) 2004-12-30 2006-07-06 Coggio William D Low refractive index fluoropolymer compositions having improved coating and durability properties
US9028123B2 (en) 2010-04-16 2015-05-12 Flex Lighting Ii, Llc Display illumination device with a film-based lightguide having stacked incident surfaces
JP2013525955A (ja) 2010-04-16 2013-06-20 フレックス ライティング ２，エルエルシー フィルムベースのライトガイドを備える照明デバイス
WO2011130720A2 (en) 2010-04-16 2011-10-20 Flex Lighting Ii, Llc Sign comprising a film-based lightguide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916806D0 (en) * 1989-07-22 1989-09-06 Univ Wales Medicine Modified proteins
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase

Also Published As

Publication number Publication date
WO2000012754A8 (en) 2000-08-10
AU5855899A (en) 2000-03-21
WO2000012754A1 (en) 2000-03-09
EP0984070A1 (en) 2000-03-08
UY25687A1 (es) 2000-03-31

Similar Documents

Publication Publication Date Title
AR030236A1 (es) Moléculas similares a il-17 y usos de las mismas
BRPI0413582A (pt) compostos, composições e métodos para inibir a atividade de proteasome
NO20081067L (no) Behandling med dihydropyndinkalsiumkanalblokkere og omega 3-fettsyrer, og et kombinasjonsprodukt derav
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
ATE330032T1 (de) Verfahren zur erhaltung der dns-integrität
ES2043626T3 (es) Procedimiento para obtener un preparado farmaceutico.
ES520857A0 (es) Procedimiento para la produccion de eteres alquilterbutilicos en presencia de butadieno.
BR112022005711A2 (pt) Métodos e composições para tratar uma doença ou transtorno
DE60333901D1 (de) Verfahren zur reduzierung der angiogenese
DK1509618T3 (da) Autoimmune sygdomme og NADPH-oxidasedefekter
CO5090889A1 (es) Metodo para identificar sustancias para el tratamiento de transtornos asociados con apoptosis mediada por c-jun
ECSP003707A (es) Diazepanes
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
UY26265A1 (es) Compuestos calciolíticos
DK1157159T3 (da) Linoleums-fladestruktur uden bærer og fremgangsmåde til fremstilling heraf
DE69923559D1 (de) Methoden zur inhibierung von helicobacter pylori
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
BR0113266A (pt) Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
AR046245A1 (es) Sales de calcio de rabeprazol
CU23062A3 (es) Metodo de tratamiento de las plantas azucareras para mejorar el contenido de azucar.
AR030750A1 (es) 1-amino-alquilciclohexanos como agentes tripanocidas
ATE392150T1 (de) Verfahren und formulierungen, die sich für die reduktion des cholesteringehalts von eigelb eignen
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar
AR026767A1 (es) Moleculas similares a antagonistas de receptores de interleukin-1 y usos de las mismas